Search

Your search keyword '"S. Meckling"' showing total 3 results
Start Over Author "S. Meckling"
3 results on '"S. Meckling"'

1. Malignant supratentorial glioma in the elderly: Is radiotherapy useful?

Author

O. Dold, Peter A. Forsyth, Neil A. Hagen, P. Brasher, and S. Meckling

Subjects
Male, medicine.medical_specialty, Time Factors, Neurology, Radiography, medicine.medical_treatment, Central nervous system disease, Internal medicine, Glioma, Biopsy, medicine, Humans, Aged, Aged, 80 and over, medicine.diagnostic_test, Brain Neoplasms, business.industry, Incidence (epidemiology), medicine.disease, Survival Analysis, Surgery, Cancer registry, Radiation therapy, Female, Neurology (clinical), business
Abstract

To determine (1) if radiotherapy (RT) improves survival or neurologic function in elderly patients with malignant supratentorial glioma (MSG) and (2) which prognostic factors predict survival.The prevalence of MSG is increasing because both the number of elderly patients and the age-adjusted incidence are increasing. Because age is a powerful negative prognostic factor in MSG, it is not clear if RT is useful in the elderly.We retrospectively studied 103 patients from the Southern Alberta Cancer Registry diagnosed January 1, 1978, to December 31, 1993, aged 70 yrs, with MSG in whom sufficient clinical and follow-up information was available. Multiple treatment and patient factors were compared with survival and neurologic function score. Diagnosis was confirmed in 15 (14.6%) by biopsy, in 66 (64.1%) by resection, and in 22 (21.4%) by clinical course and typical radiographic appearance only.All patients died and median survival was 3.9 months. Better neurologic function at diagnosis and administration of RT were independently associated with significantly longer survivals (p = 0.001 and0.001; log rank test). However, RT was only associated with longer survival in patients aged less than 80 years. Neurologic status only rarely improved following RT.The prognosis for elderly patients with MSG is poor. RT is unlikely to benefit patients who are aged 80 years or older. RT has a short-lived benefit for patients who are functionally disabled.

Published
1996

2. Abstracts of the 6th Canadian Neuro-Oncology Meeting May 18–21, 1994 Lake Louise, Alberta

Author

Kozo Fukuyama, Kazuhito Matsuzawa, Sherri Lynn Hubbard, Peter Dirks, James T. Rulka, K. Maisuzawa, S. L. Hubbard, J. T. Rutka, R. F. Del Maestro, I. S. Vaithilingam, W. McDonald, J. B. Weiss, T. Mikkelsen, E. Kohn, K. Nclson, M. L. Rosenblum, Abhijit Guha, Steve Shamah, Charles Stiles, N. P. Dooley, G. H. Baltuch, M. Roslworowski, J. G. Villemure, V. W. Yong, G. Baltuch, M. Rostworowski, W. T. Couldwell, D. R. Hinton, M. H. Weiss, R. Law, William T. Couldwell, David R. Hinton, Ron Law, Martin H. Weiss, J. M. Piepmeier, P. E. Pedersen, C. A. Greer, PB Dirks, SL Hubbard, A. Taghian, W. Budach, J. Freeman, D. Gioioso, H. D. Suit, J. Turner, G. Barron, P. Zia, C. S. Wong, J. Van Dyk, M. Milosevic, N. J. Laperriere, S. T. Myles, C. Lauryssen, E. G. Shaw, B. W. Scheithauer, V. Suman, J. Katzmann, M. Preul, G. Shenouda, A. Langleben, D. Arnold, C. Watling, D. van Meyel, D. Ramsay, G. Cairncross, J. P. Bahary, I. Wainer, M. Pollak, B. Leyland-Jones, A. Tsatoumas, A. Choi, S. S. Rosenfeld, G. Y. Gillespie, C. L. Gladson, J. M. Drake, H. J. Hoffman, R. P. Humphreys, S. Holowka, D. S. Fullon, R. C. Urtasun, Mark G. Hamilton, S. Beals, E. Joganic, R. Spetzler, J. C. Buckner, P. L. Schaefer, R. P. Dinapolit, J. R. O'Fallon, P. A. Burch, C. L. Chandler, K. Hopkins, H. B. Coakham, J. Bullimore, J. T. Kemshead, Mark Bernstein, Normand Laperriere, Stephen MeKenzie, Jennifer Glen, D. Lee, D. Macdonald, P. K. Sneed, P. G. Gulin, D. A. Larson, M. W. McDermott, M. D. Prados, W. M. Wara, K. A. Weaver, L. Gaspar, L. Zamorano, L. Garcia, F. Shamsa, C. Warmelink, D. Yakar, J. A. Espinosa, L. Souhami, J. L. Caron, A. Olivier, E. B. Podgorsak, C. Lindquist, J. S. Loeffler, L. D. Lunsford, H. B. Newton, M. D. Kotur, A. C. Papp, T. W. Prior, N. Roosen, R. Chopra, J. Windham, Matthew Parliament, Allan Franko, Brace Mielke, W. Feindel, D. Tampieri, L. L. Mechtler, S. Wilheim-Leitch, K. Shin, W. R. Kinkel, M. A. Hammoud, R. Sawaya, W. Shi, P. P. Thall, N. Leeds, M. Patel, B. Truax, P. Kinkel, T. M. Cheng, B. P. O'Ncill, D. G. Piepgras, P. J. Frost, W. J. S. Simpson, D. G. Payne, M. Pintilie, D. A. Ramsay, J. Bonnin, D. R. Macdonald, L. Assis, J. G. Villemurel, S. Choi, R. Leblancl, A. Olivieri, G. Bertrandl, J. Hazel, W. Grand, R. Plunkett, F. Munschauer, P. Ostrow, L. Mcchtler, S. Meckling, O. Dold, P. Forsyth, P. Brasher, N. Hagen, L. P. Hudson, A. L. Cooke, P. J. Muller, W. Tucker, R. Moulton, M. Cusimano, J. Bilbao, P. A. Pahapill, C. Sibala, C. West, B. Fisher, W. Pexman, J. Taylor, T. Lee, Stephen W. McKenzie, Tian Zengmin, Liu Zonghui, S. Kirby, B. J. Fisher, D. J. Stewart, W. Roa, B. McClean, S. Buckney, S. Halls, S. Richardson, B. C. Wilson, A. C. Whitton, R. D. Borr, H. Rhydderch, T. Case, D. Feeny, W. Furlong, and G. W. Torrance

Subjects
Cancer Research, medicine.medical_specialty, Neurology, Oncology, business.industry, Neuro oncology, Family medicine, medicine, Environmental ethics, Neurology (clinical), business
Published
1994

3. Malignant supratentorial glioma in the elderly: is radiotherapy useful?

Author

Meckling S, Dold O, Forsyth PA, Brasher P, and Hagen NA

Subjects
Aged, Aged, 80 and over, Brain Neoplasms mortality, Female, Glioma mortality, Humans, Male, Survival Analysis, Time Factors, Brain Neoplasms radiotherapy, Glioma radiotherapy
Abstract

Objectives: To determine (1) if radiotherapy (RT) improves survival or neurologic function in elderly patients with malignant supratentorial glioma (MSG) and (2) which prognostic factors predict survival., Background: The prevalence of MSG is increasing because both the number of elderly patients and the age-adjusted incidence are increasing. Because age is a powerful negative prognostic factor in MSG, it is not clear if RT is useful in the elderly., Design/methods: We retrospectively studied 103 patients from the Southern Alberta Cancer Registry diagnosed January 1, 1978, to December 31, 1993, aged 70 yrs, with MSG in whom sufficient clinical and follow-up information was available. Multiple treatment and patient factors were compared with survival and neurologic function score. Diagnosis was confirmed in 15 (14.6%) by biopsy, in 66 (64.1%) by resection, and in 22 (21.4%) by clinical course and typical radiographic appearance only., Results: All patients died and median survival was 3.9 months. Better neurologic function at diagnosis and administration of RT were independently associated with significantly longer survivals (p = 0.001 and < 0.001; log rank test). However, RT was only associated with longer survival in patients aged less than 80 years. Neurologic status only rarely improved following RT., Conclusions: The prognosis for elderly patients with MSG is poor. RT is unlikely to benefit patients who are aged 80 years or older. RT has a short-lived benefit for patients who are functionally disabled.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results